SNIPPET: Oral nicotinamide (2000 mg/day) and Polypodium leucotomos extract (480 mg/day) both increased UVA minimal erythema dose by 26% in a randomized trial of 50 volunteers, but neither supplement reduced UVA-induced DNA damage (thymidine dimers) in skin or urine, raising questions about their actual cancer-prevention mechanisms.

Nicotinamide and Polypodium Leucotomos Boost UV Tolerance but Fail to Block DNA Damage

THE PROTOHUMAN PERSPECTIVE#

Here's the uncomfortable truth for anyone stacking oral photoprotectants this summer: your skin may look less red, but the DNA damage is still happening underneath. A March 2026 randomized trial just showed that both nicotinamide (vitamin B3) and Polypodium leucotomos extract — the two most popular oral sun-defense supplements — reduce UVA-induced erythema by 26%, yet neither moves the needle on thymidine dimer formation, the actual molecular fingerprint of UV-induced DNA lesions that drive skin cancer. This matters because the entire premise of oral photoprotection in the biohacking community rests on the assumption that less redness means less damage. It doesn't. The erythema pathway and the DNA damage pathway appear to be decoupled, at least under UVA exposure. For anyone optimizing skin longevity — and that should be everyone reading this — the implications are significant. Suppressing the inflammatory signal without suppressing the mutagenic hit is, at best, incomplete protection. At worst, it's a false sense of security.

THE SCIENCE#

Oral Photoprotection: What the New Data Actually Shows#

Oral nicotinamide (NAM) is a form of vitamin B3 that feeds directly into NAD+ synthesis — the coenzyme central to cellular energy metabolism, DNA repair via PARP enzymes, and sirtuin-mediated stress responses. Polypodium leucotomos extract (PLE) is a fern-derived antioxidant with documented immunomodulatory and anti-inflammatory properties. Both have been marketed aggressively as "sunscreen pills," though no regulatory body endorses that framing.

The March 2026 trial published in Photochemical & Photobiological Sciences enrolled 50 healthy volunteers with Fitzpatrick phototypes I–III into a randomized intraindividual design ^[1]. Half received NAM at 2000 mg daily; half received PLE (Heliocare Advanced) at 480 mg daily for 30 days. UVA-induced erythema was quantified via minimal erythema dose (MED), and DNA damage was measured through thymidine dimers (TT-dimers) in both skin biopsies and urine.

Both groups saw their MED increase by 26%. NAM pushed median MED from 27.7 J/cm² to 34.8 J/cm² (p = 0.0008). PLE matched that exactly — 27.7 to 34.8 J/cm² (p = 0.0002). Statistically significant. Clinically meaningful for erythema. But here's where it gets complicated.

Neither NAM nor PLE reduced TT-dimer levels in skin biopsies (both p = 0.15) or urine (NAM: p = 0.89; PL: p = 0.30). Not a trend toward significance. Not even close. The DNA damage marched on regardless of supplementation.

The UVB Story Is Even Messier#

Wait, let me be more precise here. The same research group published companion data from a UVB-focused intraindividual trial in late 2025 ^[2]. Under narrowband UVB exposure, PLE increased MED by 29% (p = 0.00018), but NAM failed entirely — no significant change in erythema (p = 0.533). And again, neither treatment affected TT-dimer formation.

So NAM protects against UVA-induced redness but not UVB-induced redness. PLE protects against both. And neither protects against the DNA damage from either wavelength. The mechanism of erythema suppression appears to operate through anti-inflammatory or antioxidant pathways — quenching reactive oxygen species, modulating NF-κB signaling — that run parallel to, not upstream of, cyclobutane pyrimidine dimer formation.

Why Erythema Suppression ≠ DNA Protection#

Look, the NMN and NAM crowd is going to love the erythema data — and they should, just not for the reasons they think. A 26% increase in MED is real. It means you can tolerate roughly a quarter more UVA exposure before your skin visibly reddens. But erythema is an inflammatory response mediated largely by prostaglandins and cytokines. It's a downstream consequence of UV damage, not the damage itself.

TT-dimers — cyclobutane pyrimidine dimers formed between adjacent thymidine bases — are the direct mutational lesion. They're repaired by nucleotide excision repair (NER), a process that's NAD+-dependent via PARP-1 activation. The theoretical case for nicotinamide was that by boosting cellular NAD+ pools, you'd accelerate NER and see fewer residual dimers. The data doesn't support this under acute UVA challenge.

One important caveat: the study authors note that NAM and PLE were not administered during the urine collection period following UV exposure ^[1]. This limits interpretation of post-irradiation repair dynamics. It's possible — though unproven — that continued supplementation during the repair window would show different results for dimer clearance kinetics.

The Broader Evidence Landscape#

A 2025 systematic review in the Journal of Drugs in Dermatology examined 21 studies on oral PLE across multiple dermatologic conditions ^[3]. The review found evidence supporting PLE's photoprotective and immunomodulatory properties across photoaging, actinic keratosis, melasma, vitiligo, and photodermatoses. Eleven of the included studies were RCTs. The safety profile was consistently favorable.

Separately, a pilot study by Villani et al. (2026) tested a topical SPF 50+ sunscreen combining PLE, ellagic acid, and niacinamide in 20 women with melasma ^[4]. MASI scores dropped 44% from baseline by week 24 (p = 0.0001). Promising — but this was uncontrolled, small, and combined three active ingredients. Impossible to isolate PLE's contribution.

COMPARISON TABLE#

THE PROTOCOL#

Based on current evidence, here's how I'd approach oral photoprotection — with appropriate caveats.

Step 1: Do not replace topical sunscreen. This is non-negotiable. Neither NAM nor PLE blocks DNA damage. Broad-spectrum SPF 30+ remains your primary defense. Apply 2 mg/cm² to all exposed skin, reapply every 2 hours during direct exposure.

Step 2: If adding oral PLE, dose at 480 mg daily. This is the dose used in the strongest trial data. Start 30 days before your highest-exposure season. PLE showed erythema protection under both UVA and UVB, which gives it an edge over NAM for sunburn prevention specifically. Take with food.

Step 3: If adding oral nicotinamide, dose at 500–1000 mg daily in divided doses. The trial used 2000 mg, but this is above what most longevity-focused protocols recommend. NAM at high doses can suppress sirtuin activity — a direct conflict with the longevity rationale many biohackers are optimizing for. I'd want to see sirtuin expression data before committing to 2 g daily long-term. 500 mg twice daily is a reasonable middle ground based on existing NAD+ repletion literature.

Step 4: Time your supplementation to continue through the UV exposure window. The trial's own limitation — stopping supplementation before the urine collection period — is instructive. If NAM's potential benefit is enhancing DNA repair post-exposure, you need circulating NAD+ during the repair window, not just before irradiation. Take your dose in the morning before sun exposure, and again after if using divided dosing.

Step 5: Monitor your skin independently of redness. Since erythema suppression may mask ongoing DNA damage, use dermatoscopic skin checks every 6–12 months. Don't let reduced redness convince you that sun exposure is now "safe." The dimers are still forming.

Step 6: Stack antioxidant support. Consider adding astaxanthin (4–12 mg daily) or sulforaphane (from broccoli sprout extract) for additional antioxidant coverage targeting different ROS pathways. These are not proven to reduce TT-dimers either, but the mechanistic rationale for complementary radical scavenging is sound.

What is the difference between nicotinamide and niacinamide for UV protection?#

They're the same molecule — nicotinamide is the international nonproprietary name, niacinamide is the cosmetic industry term. Both refer to the amide form of vitamin B3. In the context of UV protection, the oral form at pharmacological doses (500–2000 mg) is what the trials tested. The 2–5% concentrations in topical serums operate through different pathways and aren't comparable.

How does Polypodium leucotomos extract actually protect skin?#

PLE works primarily through antioxidant and immunomodulatory mechanisms. It scavenges reactive oxygen species generated by UV exposure, modulates inflammatory cytokine release, and may preserve Langerhans cell populations in irradiated skin. What it doesn't appear to do — based on two controlled trials — is prevent the formation of cyclobutane pyrimidine dimers, the direct DNA lesions caused by UV photons ^[1][2].

Why did nicotinamide fail to protect against UVB erythema but work for UVA?#

Honestly, we don't fully know yet. UVA and UVB trigger erythema through partially overlapping but distinct inflammatory cascades. UVB directly excites DNA, while UVA generates damage primarily through ROS intermediates. NAM's anti-inflammatory effects may be more relevant to the ROS-driven UVA pathway than to the direct photon absorption pathway of UVB. But I'd want to see this replicated before drawing mechanistic conclusions from a single trial.

Who should consider taking oral photoprotectants?#

Individuals at elevated skin cancer risk — Fitzpatrick types I–III, history of actinic keratoses, immunosuppressed patients, or those with unavoidable high sun exposure. The ONTRAC trial previously showed NAM at 500 mg twice daily reduced new keratinocyte carcinomas by 23% in high-risk patients. But remember: the mechanism behind that chemoprevention may not be dimer prevention. It could be immune surveillance enhancement, which these newer trials weren't designed to measure.

When should you start taking these supplements before sun season?#

The trials used a 30-day pretreatment period, and that's reasonable. PLE in particular needs time to build systemic antioxidant effects. A 5-day protocol was tested in a smaller study and showed modest MED increases ^[3], but the 30-day data is stronger. Start a month before your peak UV exposure period.

VERDICT#

Score: 6/10

The data here is genuinely important — not because it validates oral photoprotection, but because it exposes its limits. A 26% MED increase is real, measurable, and clinically relevant for erythema. But the complete failure to reduce TT-dimers in either skin or urine is a serious finding that the supplement industry will conveniently ignore. Look, I'm not saying throw out your Heliocare. I'm saying stop pretending it's a DNA shield. It's an anti-inflammatory adjunct. Useful? Yes. Sufficient? Not even close. The honest takeaway: sunscreen and clothing remain irreplaceable, and the gap between "less red skin" and "less DNA damage" is wider than anyone selling you a fern pill wants you to know.